title: Fibromyalgia syndrome: an overview of potential drug targets.
abstract: Fibromyalgia syndrome (FMS) is a chronic disease of widespread and debilitating pain. The cause of FMS is unknown and its risk factors are poorly understood. It occurs frequently in the general population where it is often co-morbid with other rheumatoid and pain disorders, and psychiatric disorders such as anxiety and depression, making diagnosis particularly difficult. Several types of drugs are used to treat FMS, but none are specifically approved for this indication. FMS appears to be strongly associated with depression or at least with some symptoms of depression, and antidepressants appear to be effective in the treatment of this disorder. The advent of new classes of antidepressants with fewer side effects than older drugs has suggested new avenues of therapy for patients diagnosed with FMS.
authors.affiliation: NeuroBiz Consulting and Communications, Les Grèzes, La Verdarié, 81100 Castres, France. mike.briley@neurobiz.com
authors.forename: Mike
authors.initials: M
authors.lastname: Briley
authors.forename: Chantal
authors.initials: C
authors.lastname: Moret
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy / Q000378:metabolism; D005356:Fibromyalgia / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009619:Nociceptors / Q000378:metabolism; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D013577:Syndrome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000928:Antidepressive Agents